Treatment with the cancer vaccine galinpepimut-S (GPS) is showing promise to potentially improve survival in people with acute myeloid leukemia (AML), a type of…
News
PANCREATIC CANCER
Checkpoint inhibitors may be effective Pan-NEN immunotherapy
Certain immunotherapies may be effective in some cases of pancreatic neuroendocrine neoplasms (Pan-NEN), a rare type of pancreatic cancer, according to a study that…
The Lundin Cancer Fund has donated $4 million to the Canadian Cancer Society to create the Glioblastoma Research Program, a five-year initiative to…
GYNECOLOGICAL CANCER
Azenosertib may be effective at treating cyclin E1+ PROC: Study
About a third of women with cyclin E1+ platinum-resistant ovarian cancer (PROC) responded to treatment with azenosertib, an experimental therapy by Zentalis. That’s according…
Researchers in Brazil have developed a large dataset of cells taken from the bone marrow of people with multiple myeloma (MM) and other blood…
The European Commission has approved Blincyto (blinatumomab) as part of a consolidation therapy regimen to reduce the risk of relapse in adults newly diagnosed…
PANCREATIC CANCER
Lixumistat shows promise as treatment for pancreatic cancer
Treatment with the once-daily oral therapy lixumistat, in addition to chemotherapy, slowed the growth of pancreatic cancer among participants with advanced disease in an…
A signaling molecule released by blood vessel cells prompts cancer cells to grow and become resistant to treatment in glioblastoma, an aggressive type of…
GYNECOLOGICAL CANCER
Sempervirine stops ovarian cancer cell growth in preclinical studies
Sempervirine, a compound isolated from a plant used in traditional Chinese medicine, inhibited the growth, spread, and development of ovarian cancer cells in cell…
Regulators in the European Union (EU) have approved Sarclisa (isatuximab) in combination with standard-of-care medications for adults newly diagnosed with multiple myeloma who…
Recent Posts
- My husband and I aren’t just each other’s caregivers; we’re care partners
- Under-the-skin myeloma therapy shows strong responses in Phase 2 trial
- Trial finds treatment eases PV symptoms despite missing main goal
- The quiet courage of taking a short break as a caregiver
- EU clears Tecvayli as solo option when myeloma returns after first treatment